| Date | Title | Description |
| 25.06.2024 | Circio´s leading position in circular RNA therapeutics highlighted by broad recent coverage in international life science industry media | Circio´s leading position in circular RNA therapeutics highlighted by broad recent coverage in international life science industry media
Tue, Jun 25, 2024 07:00 CET Report this content
Circio´s position as a pioneering player in the rapidly... |
| 02.09.2022 | Green Light for Cancer Drugs Developed by AI Specialist Owkin | Originally published by Pharma Times Online
AI biotech company Owkin has announced that two first-in-class rapid, affordable AI-based diagnostic solutions – designed to improve outcomes for patients with breast cancer and colorectal cancer... |
| 16.12.2021 | Phargentis begins clinical development of early-entry generic version of COPD treatment indacaterol/glycopyrronium and DPI device | Phargentis begins clinical development of early-entry generic version of COPD treatment indacaterol/glycopyrronium and DPI device Thu, Dec 16, 2021 08:30 CET
(16 December, 2021) Phargentis has begun clinical development of its capsule based... |
| 28.09.2021 | Amplitude CEO’s ode to scrutiny ahead of going public | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Paid Content To retain talent, employers can't skip on fertility benefits From Maven Clinic
To th... |
| 28.09.2021 | Amplitude CEO’s ode to scrutiny ahead of going public | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Paid Content Why the Electricity 4.0 moment is here From Schneider Electric
To the chagrin of man... |
| 18.08.2021 | Booster shots alone won’t protect immunocompromised people from Covid-19 | Covid-19 taught me something about second chances: In March 2020, I fought the virus and won. Barely.
But my gratitude for the chance to live, to continue to be a husband and father, and to work in the hospital again doesn’t translate into ... |
| 31.03.2021 | 54Gene, COVID-19 and the prospects of Human Biotechnology in Nigeria | By Oluwabukunmi Familoye and Ikpeme Neto
Nigeria doesn’t contribute much to the global biotech industry which is estimated to be worth $833.34 billion with a Compound Annual Growth Rate (CAGR) of over 7.02% by 2027, but this is beginning to... |
| 12.03.2021 | Quantum Computing: How It May Change The Face Of Your Business (Forever) | Ari Zoldan, CEO Quantum Media Group. |
| 04.01.2021 | News briefing: 10 years later, teplizumab gets a second shot at an FDA OK; J&J files for amivantamab approval in Europe | Teplizumab’s 10-year trek back into the R&D spotlight is getting another assist from the FDA.
The agency has provided a brief priority review schedule for the type 1 diabetes drug, according to Provention Bio. And tha... |
| 21.04.2020 | Выдача принудительных лицензий или ограничение патентной монополии на лекарства | Под угрозой выдачи принудительной лицензии производитель препарата Калетра (применяется для лечения коронавируса) дал согласие правительству Израиля на покупку дешевых дженериков в других странах. Разбираемся, какие еще есть способы огранич... |
| 09.08.2019 | Biotech researchers venture into the wild to start their own business | Jorge Conde Contributor
Share on Twitter
Jorge Conde is a General Partner at Andreessen Horowitz where he leads investments at the cross section of biology, computer science and engineering.
Much of Silicon Valley mythology is centered on t... |
| 17.12.2018 | Precision Medicine: the next revolution in healthcare | Precision Medicine: the next revolution in healthcare
17-12-2018
In recent years, we have witnessed a remarkable healthcare revolution. Thanks to advances in genetic analysis, molecular biology and cell science, we now know more about the h... |
| 03.12.2018 | Supreme Court decision signals bad news for patent holders | Supreme Court decision signals bad news for patent holders
03-12-2018
The UK Supreme Court issued its decision today on the Warner Lambert vs Generics (UK) Ltd t/a Mylan. The decision concerns Swiss-form patent claims that relate to a speci... |
| 29.11.2018 | C4XD forms discovery partnership with AI company GTN | London, 29th November 2018
C4X Discovery has entered into a drug discovery partnership with artificial intelligence (AI) company GTN.
The partnership aims to maximise insights from shape-based chemistry, and generate novel drug candidates... |
| 26.04.2018 | Pharmalittle: FDA probes safety of Parkinson’s drug; Koch brothers push new ‘right to try’ ads | Hello, everyone, and how are you this morning? We are doing just fine, thank you, courtesy of a warm and shiny sun enveloping the calm and quiet Pharmalot campus. Our short person has departed for the local schoolhouse and the official masc... |
| 29.03.2018 | Watch out Alnylam/Ionis: Pfizer’s positive PhIII tafamidis data makes drug a new rival | Pfizer $PFE reported out some good news from a late-stage trial testing its drug tafamidis against a rare condition that leads to heart failure. The positive results of the Phase III study have both Alnylam $ALNY and Ionis $... |
| 05.03.2018 | Pharmalittle: Did an acne drug make a teen commit murder? U.K. wants to remain part of EMA, after all | Good morning, everyone, and welcome to another working week. We hope the weekend was relaxing and restful, because that oh-so-familiar routine of deadlines, meetings, and the like has predictably returned. Of course, this leaves us with no ... |
| 08.02.2018 | Scotland’s TCB inks CAR-T deal with Japan’s NIPRO | Scotland’s TC Biopharm (TCB) has secured a major investment from Japan with a deal centered on developing a novel gamma-delta CAR-T therapy to treat cancer, as well as a grant from Scottish Enterprise worth £2.7 million to fund preclinical ... |
| 08.02.2018 | Scotland’s TCB inks CAR-T deal with Japan’s NIPRO | Scotland’s TC Biopharm (TCB) has secured a major investment from Japan with a deal centered on developing a novel gamma-delta CAR-T therapy to treat cancer, as well as a grant from Scottish Enterprise worth £2.7 million to fund preclinical ... |
| 11.12.2017 | Pharmalittle: Sanofi spars with Philippines over dengue vaccine; Niacor rises 809 percent | Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, although some were quite busy, thanks to the American Society of Hematology gathering that got under way (you can read... |
| 14.11.2017 | Age of Discovery (PharmaTimes, November 2017) |
Five years on from Pfizer selling Discovery Park, the site’s current chief executive Toby Hunter tells PharmaTimes about the plans for its future.
With around 150 companies working in 14 buildings over 440 acres, and several blockbuster ... |
| 14.11.2017 | Age of Discovery (PharmaTimes, November 2017) |
Five years on from Pfizer selling Discovery Park, the site’s current chief executive Toby Hunter tells PharmaTimes about the plans for its future.
With around 150 companies working in 14 buildings over 440 acres, and several blockbuster ... |
| 11.04.2017 | Pharmalot, Pharmalittle: Opdivo’s still too expensive for the UK | Good morning, everyone. Damian Garde here, in for Ed Silverman once more, and with another round of headlines to get your day started.
UK regulators say Bristol-Myers Squibb’s blockbuster cancer drug Opdivo is too expensive for patients wit... |
| 27.01.2017 | Innovation in ADHD: Is it just more of the same? | Released Friday, the authors project an 8.5 percent compound annual growth rate (CAGR) over the next seven years, driven by increased awareness and a greater willingness to treat the condition with drugs, especially in the adult population.... |
| 02.12.2016 | Pharmalot, Pharmalittle: Allergan CEO predicts Trump will be ‘vicious’ on drug pricing | And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. And our agenda is rather modest. We expect to spend hours raking millions of lea... |
| 30.11.2016 | Pharmalot, Pharmalittle: India is now classifying dozens of drug makers as high-risk | Rise and shine, everyone, another busy day is on the way. This is especially true on the Pharmalot campus, where the short person has long since left for the local schoolhouse and the official mascots have tired of chasing chipmunks and squ... |
| 28.11.2016 | Pharmalot, Pharmalittle: J&J looks to take over Actelion | Good morning, everyone, and welcome to another working week. We hope the weekend respite, which was extended on this side of the pond, was delightful and invigorating. Of course, that break is now in the rearview mirror as the usual routine... |
| 23.11.2016 | Pharmalot, Pharmalittle: Handful of doctors responsible for high levels of fentanyl prescriptions | Hello, everyone, and how are you today? This may be the middle of the week for many people, but on this side of the pond, the pace is slowing down — somewhat — as a holiday nears. A Wild Turkey moment, as some say. As for us, we will be tak... |
| 21.11.2016 | Pharmalot, Pharmalittle: FTC is ‘aware’ of concerns over possible Mylan antitrust violations | Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, since the usual routine of meetings, deadline and whatnot has now returned, despite the shortened week on this side of... |
| 15.11.2016 | Pharmalot, Pharmalittle: The ‘Right to Try’ movement is spreading to Canada | Hello, everyone, and how are you today? We are just fine, thank you, despite forecasts of impending doom and the steady rain drenching the Pharmalot campus. After all, as the Morning Mayor would say: “Every brand new day should be unwrapped... |
| 14.11.2016 | Pharmalot, Pharmalittle: Drug makers warn German price controls will threaten access | Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and provided an opportunity to collect your wits, since these will be greatly needed in coming days. With this in mind, we will down anoth... |
| 09.11.2016 | Pharmalot, Pharmalittle: Drug stocks rally on Trump presidential victory | And so, the morning after has arrived. Nothing like a surprise, yes? Well, the world will continue to spin no matter what, so adjust your seat belt accordingly. If nothing else, this calls for a few cups of stimulation. Remember, no prescri... |
| 07.11.2016 | Pharmalot, Pharmalittle: Battle over California’s Prop 61 for lower drug prices is tightening | Good morning, everyone, and welcome to another working week. And this should be an exciting one, yes? After all, there is an election taking place and who knows what may happen. All the more reason to start quaffing cups of stimulation to p... |
| 04.11.2016 | Pharmalot, Pharmalittle: Feds may soon charge generic drug makers for price fixing | And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Our agenda is rather modest, as usual. We plan to rake mounds of leaves, catch u... |
| 01.11.2016 | Pharmalot, Pharmalittle: Is the 21st Century Cures bill in doubt over drug prices? | Top of the morning to you, and a fine one it is. A warm sun is shining here on the Pharmalot campus, where the shortest person has left for the local schoolhouse and the official mascots are snoozing contentedly on the official Pharmalot of... |
| 24.10.2016 | Pharmalot, Pharmalittle: DEA slowed enforcment even as opioid epidemic raged | Hello, everyone, and welcome to another working week. We hope the weekend respite was enjoyable and refreshing, because that familiar routine of meetings, deadlines, and the like has returned with a vengeance. And there is nothing like a re... |
| 21.10.2016 | Pharmalot, Pharmalittle: Alkermes depression drug now looks promising, but will FDA bite? | And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Our agenda is somewhat ambitious. We plan to take Mrs. Pharmalot pear picking — ... |
| 20.10.2016 | Pharmalot, Pharmalittle: Chicago plans to require licenses for sales reps who market opioids | Rise and shine, everyone, another busy day is on the way. And after the presidential debate last night, being busy may be a good thing. Another good thing, of course, is a delicious cup of stimulation, which we are quaffing as we compose ou... |
| 13.10.2016 | Pharmalot, Pharmalittle: New bill would create review board for drug prices | Hello, everyone, and nice to see you again after a brief respite. Although we made good use of our time away, we know the world continued spinning, so we have gathered a menu of tidbits that, hopefully, catch you up on a variety of events a... |
| 11.10.2016 | Pharmalot, Pharmalittle: Some docs say more patients want do-it-yourself EpiPens | Hello, everyone, and nice to see you again after an extended weekend. Of course, playing catch-up is now a challenge, so we are fortifying ourselves for the big scramble with several cups of stimulation — our flavor, once again, is Pumpkin ... |
| 06.10.2016 | Pharmalot, Pharmalittle: Alnylam stock plunges after key clinical trial is ended | Hello, everyone, and how are you today? We are just fine, thank you. A bright shiny sun is warming our Pharmalot campus, which is rather quiet now that the short person has left for the local schoolhouse and the mascots are snoozing in thei... |
| 28.09.2016 | Pharmalot, Pharmalittle: Patient advocacy groups are failing their members in the drug pricing debate | Rise and shine, everyone, another busy day is on the way. We apologize for the late start today, but we are wrapping up yet another road trip and encountered aggravating traffic before we could attempt our usual morning routine. Nonetheless... |
| 27.09.2016 | Pharmalot, Pharmalittle: Most Californians support proposed law to limit drug prices | Hello, everyone, and how are you this morning? We are just fine, thank you, as we prepare for another busy day. As usual, there is much to be done and, no doubt, you can relate. However, our usual routine will be abbreviated as we prepare t... |
| 26.09.2016 | Pharmalot, Pharmalittle: Pfizer decides not to split into two companies | Good morning and welcome to another working week. We hope the weekend respite, which went by rather quickly, was refreshing and invigorating, because the usual routine of meetings, deadlines, and whatnot has returned. But you knew this woul... |
| 23.09.2016 | Pharmalot, Pharmalittle: Mylan’s parent bloggers feel jilted thanks to price hikes | And so, another working week will soon draw to a close. Not a moment too soon, yes? After all, it has been a busy few days. This is, you may recall, our treasured signal to daydream about weekend plans. As usual, our agenda is rather modest... |
| 21.09.2016 | Pharmalot, Pharmalittle: Mylan CEO’s mom helped push EpiPen to schools | Hello, everyone, and welcome to the middle of the week. You made it this far, which deserves congratulations and a little nudge to keep forging ahead. And why not? Just consider the alternatives. On that note, please join us for a delicious... |
| 19.09.2016 | Pharmalot, Pharmalittle: Glaxo CEO says drug makers must be ‘empathetic’ about pricing | Rise and shine, everyone, another working week is getting underway. Unfortunately, a spot of rain is dotting the Pharmalot campus, although our spirits remain sunny. And why not? Every brand new day should be unwrapped like a precious gift.... |
| 13.09.2016 | Pharmalot, Pharmalittle: Prisons struggle to provide costly hepatitis C drugs | Good morning, everyone, and how are you today? We are just fine, thank you, although a bit busier than usual as we get ready for another public chat. With that in mind, we have assembled a slightly abbreviated menu of tidbits for your enjoy... |
| 12.09.2016 | Pharmalot, Pharmalittle: Teva expects FDA to speed review of its generic EpiPen | Good morning, everyone, and welcome to another working week. The usual weekend respite went by quickly, did it not? As our short person exclaimed: “Oh, no!” Well, these things happen. And of course, this can mean only one thing — time to re... |
| 09.09.2016 | Pharmalot, Pharmalittle: Pfizer CEO says Clinton drug pricing plan is ‘very negative’ | And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is very modest. We hope to catch up on our naps and our reading, a... |
| 07.09.2016 | Pharmalot, Pharmalittle: Immunotherapy is complicating clinical trial designs | Hello, everyone, and how are you today? A bunch of clouds are hovering over the serene Pharmalot campus this morning, but a delicious cool breeze is also wafting by. We take what we can get, as they say. Speaking of which, it is also time t... |
| 06.09.2016 | Pharmalot, Pharmalittle: India plans tougher penalties for bribing doctors | Good morning, everyone, and welcome back. We hope the long holiday weekend was enjoyable and relaxing, but all things must pass, as they say, which means the time has come to resume the unrelenting routine of deadlines, meetings, and the li... |
| 31.08.2016 | Pharmalot, Pharmalittle: FDA approves a biosimilar version of Enbrel | Hello, everyone, and welcome to the middle of the week. Although this is often a slow time of year, it has been a busy few days, lately, yes? Well, that can only mean one thing — time for another cup of stimulation. The neurons need a littl... |
| 26.08.2016 | Pharmalot, Pharmalittle: Mylan CEO claims ‘no one’s more frustrated than me’ | And so, another working week is about to draw to a close. Not a moment too soon, yes? After a busy few days, this is an opportunity to start daydreaming about weekend plans. Our agenda is rather modest. We plan to shepherd one of the short ... |
| 25.08.2016 | Pharmalot, Pharmalittle: Most UK docs can’t prescribe what they want due to shortages | Hello, everyone, and welcome to another busy day. All EpiPen, all the time, appears to be a new slogan. Nonetheless, the world continues to spin elsewhere, and so we have managed to gather a few other items of interest to help you along. As... |
| 17.08.2016 | Pharmalot, Pharmalittle: Another analysis finds new cholesterol drugs are not cost-effective | Hello, everyone, and welcome to the middle of the week. Yet another steamy day is on the way, and we are trying to stay cool with cups of iced stimulation. We hope you are doing the same. We should note that we will be taking an extended br... |
| 11.08.2016 | Pharmalot, Pharmalittle: Valeant under criminal investigation for defrauding insurers | Good morning, everyone, and how are you today? We are doing reasonably well, thank you, given an especially busy week. But this is to be expected in a busy world, yes? So please join us as we cope by quaffing yet another cup of stimulation.... |
| 05.08.2016 | Pharmalot, Pharmalittle: Bristol-Myers cancer drug misses main goal in late-stage study | And so, another working week will soon draw to a close. And not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda includes indulging the shortest of short people at a sugary de... |
| 02.08.2016 | Pharmalot, Pharmalittle: Gilead’s preventive HIV pill must be covered in England | Rise and shine, everyone, another busy day is on the way. Yes, it may be summertime, but the world is still spinning, which means there is much to do. Even our short people are busily engaged in productive activities. As for us, yes, we are... |
| 26.07.2016 | Pharmalot, Pharmalittle: Arkansas obtained Pfizer drug for executions | Rise and shine, everyone, another steamy day is on the way. Yes, a heat wave continues to envelop the Pharmalot campus, where the shortest person is sleeping in and the official mascots are already exhausted. As for us, we are quaffing cups... |
| 25.07.2016 | Pharmalot, Pharmalittle: Did Abbott rep in India kill himself over sales goals? | Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing, despite the heat, because the usual routine of meetings and deadlines has returned. And the heat is still on, as they say. Well, to cope,... |
| 22.07.2016 | Pharmalot, Pharmalittle: FDA overlooks troubles at Chinese supplier to avoid shortages | And so, another working week will soon draw to a close. This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. Besides hoping to keep cool, we plan to catch up on sundry chores and errand... |
| 21.07.2016 | Pharmalot, Pharmalittle: Biogen CEO to leave, Theranos hires compliance execs | Hello, everyone, and how are you today? We are just fine, thank you, as a warm and shiny sun envelops the Pharmalot campus, where the shortest of short people has left for a summer activity and the official mascots are snoozing away. As for... |
| 20.07.2016 | Pharmalot, Pharmalittle: Novartis stops making TB drugs in Pakistan, prompting fear of a health crisis | Good morning, everyone, and welcome to the middle of the week. Somehow, we all made it this far, so why not celebrate with a cup or three of stimulation? After all, there is much more to be done and, unlike the official Pharmalot mascots, w... |
| 18.07.2016 | Pharmalot, Pharmalittle: FDA reviewers say Valeant drug carries suicide risks | Good morning, everyone, and welcome to another working week. We hope the weekend was relaxing and invigorating. Our own respite was refreshing, especially having taken an extended break. Now, though, that familiar routine of deadlines, meet... |
| 13.07.2016 | Pharmalot, Pharmalittle: Pharma backs patients, docs who oppose Medicare Part B overhaul | Good morning, everyone, and how are you today? We are just fine, thank you, especially since we plan to take an extended weekend. This means that our usual dispatches will not return until next Monday. But a respite, however brief, is alway... |
| 11.07.2016 | Pharmalot, Pharmalittle: Purdue delayed reporting excessive OxyContin prescribing | Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and inspiring, because the familiar routine has now returned. One consolation — at least for those of you toiling in the same region a... |
| 08.07.2016 | Pharmalot, Pharmalittle: Duchenne drug rejected in US is available in England | And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. And our agenda is rather modest. We plan to spend time with two of our short peo... |
| 06.07.2016 | Pharmalot, Pharmalittle: Medivation to start takeover talks with Sanofi and others | Rise and shine. Another busy day is on the way. And this appears it will also be a steamy one here on the Pharmalot campus, where the short people are sleeping in and the official mascots are chatting around the water bowl. As for us, we ar... |
| 05.07.2016 | Pharmalot, Pharmalittle: Was the FDA commissioner paid by drug makers last year? | Hello, everyone, and nice to see you again. We hope the extra-long weekend respite was relaxing and invigorating, because the familiar routine of meetings, deadlines, and whatnot has returned. This is, of course, a short week on this side o... |
| 01.07.2016 | Pharmalot, Pharmalittle: Pharma paid UK health care providers $450 million last year | And so, another working week is drawing to a close. Yes, we indicated yesterday we would be absent today, but things have a way of changing. So here we are. But this gives us another opportunity to wish you an enjoyable weekend, especially ... |
| 28.06.2016 | Pharmalot, Pharmalittle: Endo may sell assets as reliance on price hikes wanes | Hello, everyone, and how are you this morning? We are just fine, thank you, despite the cloudy skies hovering over the Pharmalot campus. As always, our spirits remain sunny. After all, as the morning mayor used to say: Every brand new day s... |
| 24.06.2016 | Morning Read: Brexit win throws drug regulation, VC investment in UK life sciences into question | “Key questions about the regulation of medicine, access to the single market and talent, intellectual property and the precise nature of the future relationship of the UK with Europe are now upon us.”
Sarah Hanson, Head of UK Lifesciences a... |
| 24.06.2016 | Pharmalot, Pharmalittle: Will Brexit force European drug regulators to leave London? | And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We hope to catch up on reading, manicure the Pha... |
| 23.06.2016 | Pharmalot, Pharmalittle: AstraZeneca takes $80 million hit on ‘ineffective’ flu vaccine | Rise and shine, everyone, another busy day is on the way. Busy for some people, anyway. Now that the local schoolhouse has emptied out, the shortest of our short people is slumbering for exceedingly long hours. We are jealous and taking com... |
| 22.06.2016 | Pharmalot, Pharmalittle: India revising laws to upgrade drug safety | Hello, folks, and how are you today? ’Tis the middle of the week, which calls for a celebratory cup of stimulation. After all, you made it this far, so why not forge ahead? Besides, a warm, shiny sun is enveloping the Pharmalot campus, whic... |
| 20.06.2016 | Pharmalot, Pharmalittle: Clinton gets the most pharma donations of any candidate | Hello, everyone, and welcome to another working week. It’s nice to see you again after our extended respite, which was exciting and fast-paced. Now, though, the usual routine has returned. But we all knew this would happen, yes? So as a shi... |
| 13.06.2016 | Pharmalot, Pharmalittle: First cholera vaccine is approved by FDA | Good morning, everyone, and welcome to another working week. We hope the weekend respite was exhilarating and refreshing, because that familiar routine of meetings and deadlines and growing to-do lists has now returned. But you knew this wo... |
| 10.06.2016 | Pharmalot, Pharmalittle: Are too many companies chasing the same kind of cancer drug? | And so, another working week will soon draw to a close. Not a moment, too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather busy. We hope to escort Mrs. Pharmalot to a rent party,... |
| 09.06.2016 | Pharmalot, Pharmalittle: Pharma ‘fighting back’ against pricing criticism | Hello, everyone, and how are you today? We are just fine, thank you. The Pharmalot campus is notably quiet this morning, since the shortest of the short people has left for the local schoolhouse, the official mascots are snoozing away, and ... |
| 08.06.2016 | Morning Read: Medical device M&A includes Medtronic orthopedics deal, Zimmer’s $1B offer for LDR | LIFE SCIENCES
A phase 3 study of 1,670 patients to assess an injectible rheumatoid arthritis drug jointly developed by Johnson & Johnson and GSK showed the drug slowed joint damage and improved symptoms. — Reuters
Allergan secured appro... |
| 08.06.2016 | Pharmalot, Pharmalittle: FDA staff questions effectiveness of Merck antibiotic | Good morning, everyone, and welcome to the middle of the week. Getting this far is an accomplishment, and so we are celebrating with a cup of stimulation. After all, consider the alternatives. Thankfully, the local water company is not dril... |
| 06.06.2016 | Pharmalot, Pharmalittle: Rising prices for combo cancer drugs pose a dilemma | Good morning, everyone, and welcome to another working week. We hope the weekend was relaxing and invigorating because the usual routine has returned. And the usual frenetic pace is heightened thanks to a medical meeting for cancer research... |
| 03.06.2016 | Pharmalot, Pharmalittle: Immunomedics abstract booted from cancer conference | And so, another weekend will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. As of now, our agenda is unsettled. We have some reading to do and plan to tidy up... |
| 01.06.2016 | Pharmalot, Pharmalittle: Carl Icahn takes a stake in Allergan | Rise and shine, another busy day is on the way. And a fine one it is here on the Pharmalot campus, where a shiny sun and cool breeze delightfully illuminate the sounds of snoozing mascots and chirping birds. This will be an abbreviated day ... |
| 31.05.2016 | Pharmalot, Pharmalittle: Feds probe Sun Pharma over generic pricing | Good morning, everyone, and nice to see you again. We hope the long weekend respite was relaxing and invigorating, because the familiar routine of meetings, deadlines, and whatnot has now returned. But you knew this would happen, yes? Well,... |
| 31.05.2016 | Morning Read: Jazz Pharma makes $1.5B offer for Celator for acute myeloid leukemia drug | SV Life Sciences has raised $274 million in what will be its sixth fund to invest in life sciences startups. — Boston Business Journal
Amicus Therapeutics received a thumb’s up from the European Commission for its Fabry disease therapeutic ... |
| 27.05.2016 | Pharmalot, Pharmalittle: Feds probe three drug makers for links to charities | And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. And this will be a long weekend on this side of the pond, thanks to a holiday... |
| 25.05.2016 | Pharmalot, Pharmalittle: Sanofi moves to replace the Medivation board | Hello, everyone, and how are you today? A warm, shiny sun is enveloping the serene Pharmalot campus, which is exceedingly quiet, since the official mascots are snoozing on the office furniture and the local water company is drilling elsewhe... |
| 24.05.2016 | Pharmalot, Pharmalittle: Pfizer syphilis treatment in short supply | Rise and shine, everyone, another busy day is on the way. And this is shaping up to be another cloudy one here at the Pharmalot campus. Nonetheless, our spirits our sunny. You know why. The Morning Mayor taught us long ago that every brand ... |
| 23.05.2016 | Morning Read: Nvidia tech to support machine learning could create smarter medical imaging | LIFE SCIENCES
Janssen has licensed the molecule MGD015 from MacroGenics to harness its treatment potential for hematological malignancies and solid tumors. — Pharma Times
Boehringer Ingelheim has formed a collaboration with BioMed X — a gro... |
| 20.05.2016 | Pharmalot, Pharmalittle: Roche fumes as UK watchdog rejects a drug over cost | And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Our agenda is, once again, rather modest. We plan to manicure the Pharmalot camp... |
| 17.05.2016 | Pharmalot, Pharmalittle: Walmart and McKesson team up to buy generic drugs | Good morning, everyone, and how are you today? We are just fine, thank you, and chugging along, as usual. The shortest of the short people has left for the local schoolhouse, the official mascots are snoozing on the official office furnitur... |
| 12.05.2016 | Pharmalot, Pharmalittle: UK refuses to cover Bristol lung cancer drug | Rise and shine, everyone, another busy but beautiful day is unfolding. And what better way to confront the challenges and possibilities than with a delicious cup of stimulation. We are quaffing a few ourselves, to be candid. The neurons can... |
| 11.05.2016 | Pharmalot, Pharmalittle: Cigna to get discounts if cholesterol meds don’t work | Rise and shine, everyone, another busy day is on the way. And so far, this is a quieter day than expected. The local water company, such as it is, has been drilling in the vicinity of the usually serene Pharmalot campus, but perhaps this is... |
| 10.05.2016 | Pharmalot, Pharmalittle: Investors tell pharma to ‘take control’ of the pricing debate | Top of the morning to you. And a fine one it is here at the Pharmalot campus, where the shortest of short people has left for the local schoolhouse and the official mascots are snoozing away. Moreover, a warm and shiny sun, a rarity in rece... |
| 09.05.2016 | Morning Read: Takeda receives $38M from Bill and Melinda Gates for low-cost polio vaccine | LIFE SCIENCES
The U.S. Food and Drug Administration is backing away from its push to get Custom Ultrasonics to recall its 2,800 scope-cleaning machines used by hospitals and clinics. — MedPage Today
PAYERS-PROVIDERS
With the rise of cybercr... |
| 06.05.2016 | Pharmalot, Pharmalittle: Price increases on biologics diminish savings on biosimilars | And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you may recall, our treasured signal to daydream about weekend plans. Our agenda includes manicuring the Pharmalot corporate campus, hanging wit... |
| 05.05.2016 | Pharmalot, Pharmalittle: Sanofi threatens to launch a hostile bid for Medivation | Good morning, everyone, and how are you today? The sun is struggling to peek through the dense clouds covering the Pharmalot campus, where one of the short people and the official mascots are sleeping in. We, however, are pursuing our usual... |
| 29.04.2016 | Pharmalot, Pharmalittle: Medivation rejects Sanofi’s $9.3 billion bid as ‘undervalued’ | And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Our agenda is largely occupied by retrieving one of our short people from a towe... |
